ATE539764T1 - Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen - Google Patents

Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen

Info

Publication number
ATE539764T1
ATE539764T1 AT08786266T AT08786266T ATE539764T1 AT E539764 T1 ATE539764 T1 AT E539764T1 AT 08786266 T AT08786266 T AT 08786266T AT 08786266 T AT08786266 T AT 08786266T AT E539764 T1 ATE539764 T1 AT E539764T1
Authority
AT
Austria
Prior art keywords
antithrombins
mutant
treat
prevent clotting
clotting diseases
Prior art date
Application number
AT08786266T
Other languages
English (en)
Inventor
Delphine Borgel-Botbol
Veronique Feger-Picard
Elsa Bianchini
Original Assignee
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Sud Xi filed Critical Univ Paris Sud Xi
Application granted granted Critical
Publication of ATE539764T1 publication Critical patent/ATE539764T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT08786266T 2007-07-20 2008-07-18 Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen ATE539764T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290913 2007-07-20
PCT/EP2008/059486 WO2009013251A1 (en) 2007-07-20 2008-07-18 Use of mutated antithrombins for treating or preventing coagulation disorders

Publications (1)

Publication Number Publication Date
ATE539764T1 true ATE539764T1 (de) 2012-01-15

Family

ID=39111552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08786266T ATE539764T1 (de) 2007-07-20 2008-07-18 Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen

Country Status (7)

Country Link
US (1) US8741844B2 (de)
EP (1) EP2175877B1 (de)
JP (1) JP2010533684A (de)
AT (1) ATE539764T1 (de)
CA (1) CA2694047C (de)
DK (1) DK2175877T3 (de)
WO (1) WO2009013251A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081878A1 (en) * 2009-01-16 2010-07-22 Universite Paris-Sud Xi Mutated antithrombins, a process for preparing the same and their use as drugs
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9593166B2 (en) 2013-03-14 2017-03-14 Bayer Healthcare Llc Monoclonal antibodies against antithrombin β
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3904519A1 (de) 2014-10-30 2021-11-03 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
SG11201804729RA (en) 2015-12-07 2018-07-30 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
ES2992695B2 (es) * 2023-06-15 2025-07-23 Fundacion Para La Formacion E Investig Sanitarias De La Region De Murcia [Ffiis Antidoto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901917A1 (de) * 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
JP3479539B2 (ja) * 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
JPH0971600A (ja) * 1995-09-06 1997-03-18 Eisai Co Ltd ヒトアンチトロンビンｉｉｉ 変異体
AU782069B2 (en) * 1999-05-13 2005-06-30 Gtc Biotherapeutics, Inc. Transgenically produced antithrombin III and mutants thereof
US20060198836A1 (en) * 2003-07-17 2006-09-07 Smithkline Beecham Corporation Method of treating hit patients with argatroban

Also Published As

Publication number Publication date
US20100298224A1 (en) 2010-11-25
JP2010533684A (ja) 2010-10-28
CA2694047A1 (en) 2009-01-29
EP2175877A1 (de) 2010-04-21
US8741844B2 (en) 2014-06-03
CA2694047C (en) 2018-01-30
EP2175877B1 (de) 2012-01-04
WO2009013251A1 (en) 2009-01-29
DK2175877T3 (da) 2012-04-16

Similar Documents

Publication Publication Date Title
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
ATE516353T1 (de) Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
EP2390323A3 (de) Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE453642T1 (de) Substituierte phenylaminopyrimidine
CY1113580T1 (el) Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
WO2010034015A3 (en) Modulating the alternative complement pathway
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure